RNAi of bcl-2 in glioma cells is compatible with life and augments the efficiency of temozolomide treatment

Achim Temme, Frederik Enders, Ralf Wiedemuth & Gabriele Schackert
Objective: The anti-apoptotic bcl-2 is considered as promising target to sensitize glioma cells for genotoxic drugs. We sought to analyze in detail the effects of stable bcl-2-RNAi on temozolomide (TMZ) treatment of glioma cells. Method: U343-MG glioma cells harboring wild type p53 and U373-MG glioma[for full text, please go to the a.m. URL]